Trials / Terminated
TerminatedNCT05563272
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Phase 2, Multicenter, Open-Label Study of 89Zr-girentuximab for PET/CT Imaging of Tumors Likely to Express High Levels of CAIX
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Conditions
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Gastric Cancer
- Glioblastoma Multiforme
- Cholangiocarcinoma
- Hepatocellular Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Epithelial Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma
- Soft Tissue Sarcoma
- Gastric Adenocarcinoma
- Malignant Mesothelioma (MM)
- Von Hippel Lindau
- Bladder Cancer
- Bladder Urothelial Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors | On Day 0, participants will receive a single administration of 89Zr-girentuximab (37 Megabecquerel (MBq) \[1mCi\] ± 10%, containing a mass dose of 10 mg of girentuximab). |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2025-05-09
- Completion
- 2025-05-09
- First posted
- 2022-10-03
- Last updated
- 2025-07-10
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05563272. Inclusion in this directory is not an endorsement.